Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 309
Filter
Add more filters

Publication year range
1.
Am J Transplant ; 17(2): 451-461, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27456745

ABSTRACT

Clinical islet transplantation achieves insulin independence in selected patients, yet current methods for extracting islets from their surrounding pancreatic matrix are suboptimal. The islet basement membrane (BM) influences islet function and survival and is a critical marker of islet integrity following rodent islet isolation. No studies have investigated the impact of islet isolation on BM integrity in human islets, which have a unique duplex structure. To address this, samples were taken from 27 clinical human islet isolations (donor age 41-59, BMI 26-38, cold ischemic time < 10 h). Collagen IV, pan-laminin, perlecan and laminin-α5 in the islet BM were significantly digested by enzyme treatment. In isolated islets, laminin-α5 (found in both layers of the duplex BM) and perlecan were lost entirely, with no restoration evident during culture. Collagen IV and pan-laminin were present in the disorganized BM of isolated islets, yet a significant reduction in pan-laminin was seen during the initial 24 h culture period. Islet cytotoxicity increased during culture. Therefore, the human islet BM is substantially disrupted during the islet isolation procedure. Islet function and survival may be compromised as a consequence of an incomplete islet BM, which has implications for islet survival and transplanted graft longevity.


Subject(s)
Basement Membrane/metabolism , Cell Separation , Collagen Type IV/metabolism , Heparan Sulfate Proteoglycans/metabolism , Islets of Langerhans/metabolism , Laminin/metabolism , Membrane Proteins/metabolism , Adult , Cells, Cultured , Female , Humans , Islets of Langerhans/cytology , Islets of Langerhans Transplantation , Male , Middle Aged
2.
Br J Surg ; 100(4): 515-21, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23334932

ABSTRACT

BACKGROUND: Reports on the management and outcome of rare conditions, such as oesophageal atresia, are frequently limited to case series reporting single-centre experience over many years. The aim of this study was to identify all infants born with oesophageal atresia in the UK and Ireland to describe current clinical practice and outcomes. METHODS: This was a prospective multicentre cohort study of all infants born with oesophageal atresia and/or tracheo-oesophageal fistula in 2008-2009 in the UK and Ireland to record current clinical management and early outcomes. RESULTS: A total of 151 infants admitted to 28 paediatric surgical units were identified. Some aspects of perioperative management were universal, including oesophageal decompression, operative technique and the use of transanastomotic tubes. However, there were a number of areas where clinical practice varied considerably, including the routine use of perioperative chest drains, postoperative contrast studies and antireflux medication, with each of these being employed in 30-50 per cent of patients. There was a trend towards routine postoperative ventilation. CONCLUSION: The prospective methodology used in this study can help identify practices that all surgeons employ and also those that few surgeons use. Areas of clinical equipoise can be recognized and avenues for further research identified.


Subject(s)
Esophageal Atresia/surgery , Adult , Esophageal Atresia/diagnosis , Esophageal Atresia/epidemiology , Female , Gestational Age , Humans , Infant, Newborn , Ireland/epidemiology , Male , Maternal Age , Pregnancy , Prenatal Diagnosis , Preoperative Care/methods , Prevalence , Prospective Studies , Tracheoesophageal Fistula/diagnosis , Tracheoesophageal Fistula/epidemiology , Tracheoesophageal Fistula/surgery , Treatment Outcome , United Kingdom/epidemiology
3.
J Afr Earth Sci ; 86: 65-106, 2013 Oct.
Article in English | MEDLINE | ID: mdl-27065752

ABSTRACT

The East African Orogen, extending from southern Israel, Sinai and Jordan in the north to Mozambique and Madagascar in the south, is the world́s largest Neoproterozoic to Cambrian orogenic complex. It comprises a collage of individual oceanic domains and continental fragments between the Archean Sahara-Congo-Kalahari Cratons in the west and Neoproterozoic India in the east. Orogen consolidation was achieved during distinct phases of orogeny between ∼850 and 550 Ma. The northern part of the orogen, the Arabian-Nubian Shield, is predominantly juvenile Neoproterozoic crust that formed in and adjacent to the Mozambique Ocean. The ocean closed during a protracted period of island-arc and microcontinent accretion between ∼850 and 620 Ma. To the south of the Arabian Nubian Shield, the Eastern Granulite-Cabo Delgado Nappe Complex of southern Kenya, Tanzania and Mozambique was an extended crust that formed adjacent to theMozambique Ocean and experienced a ∼650-620 Ma granulite-facies metamorphism. Completion of the nappe assembly around 620 Ma is defined as the East African Orogeny and was related to closure of the Mozambique Ocean. Oceans persisted after 620 Ma between East Antarctica, India, southern parts of the Congo-Tanzania-Bangweulu Cratons and the Zimbabwe-Kalahari Craton. They closed during the ∼600-500 Ma Kuungan or Malagasy Orogeny, a tectonothermal event that affected large portions of southern Tanzania, Zambia, Malawi, Mozambique, Madagascar and Antarctica. The East African and Kuungan Orogenies were followed by phases of post-orogenic extension. Early ∼600-550 Ma extension is recorded in the Arabian-Nubian Shield and the Eastern Granulite-Cabo Delgado Nappe Complex. Later ∼550-480 Ma extension affected Mozambique and southern Madagascar. Both extension phases, although diachronous,are interpreted as the result of lithospheric delamination. Along the strike of the East African Orogen, different geodynamic settings resulted in the evolution of distinctly different orogen styles. The Arabian-Nubian Shield is an accretion-type orogen comprising a stack of thin-skinned nappes resulting from the oblique convergence of bounding plates. The Eastern Granulite-Cabo Delgado Nappe Complex is interpreted as a hot- to ultra-hot orogen that evolved from a formerly extended crust. Low viscosity lower crust resisted one-sided subduction, instead a sagduction-type orogen developed. The regions of Tanzania and Madagascar affected by the Kuungan Orogeny are considered a Himalayan-type orogen composed of partly doubly thickened crust.

4.
Diabetes Obes Metab ; 13 Suppl 1: 95-105, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21824262

ABSTRACT

Glucagon secretion is regulated by glucose but the mechanisms involved remain hotly debated. Both intrinsic (within the α-cell itself) and paracrine (mediated by factors released ß- and/or δ-cells) have been postulated. Glucagon secretion is maximally suppressed by glucose concentrations that do not affect insulin and somatostatin secretion, a finding that highlights the significance of intrinsic regulation of glucagon secretion. Experiments on islets from mice lacking functional ATP-sensitive potassium channels (K(ATP)-channels) indicate that these channels are critical to the α-cell's capacity to sense changes in extracellular glucose. Here, we review recent data on the intrinsic and paracrine regulation of glucagon secretion in human pancreatic islets. We propose that glucose-induced closure of the K(ATP)-channels, via membrane depolarization, culminates in reduced electrical activity and glucagon secretion by voltage-dependent inactivation of the ion channels involved in action potential firing. We further demonstrate that glucagon secretion measured in islets isolated from donors with type-2 diabetes is reduced at low glucose and that glucose stimulates rather than inhibits secretion in these islets. We finally discuss the relative significance of paracrine and intrinsic regulation in the fed and fasted states and propose a unifying model for the regulation of glucagon secretion that incorporates both modes of control.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Glucagon-Secreting Cells/metabolism , Glucagon/metabolism , Glucose/metabolism , KATP Channels/metabolism , Animals , Biological Transport , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2/physiopathology , Humans , Mice
5.
Nat Med ; 2(12): 1344-7, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8946833

ABSTRACT

Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a disorder of childhood associated with inappropriate hypersecretion of insulin by the pancreas. The pathogenesis of the condition has hitherto remained controversial. We show here that insulin-secreting cells from a homogeneous group of five infants with PHHI lack ATP-sensitive K+ channel (KATP) activity. As a consequence, PHHI beta-cells are spontaneously electrically active with high basal cytosolic Ca2+ concentrations due to Ca2+ influx. Our findings define the pathogenesis of this disease as a novel K+ channel disorder.


Subject(s)
ATP-Binding Cassette Transporters , Adenosine Triphosphate/physiology , Hyperinsulinism/metabolism , Hypoglycemia/metabolism , Islets of Langerhans/physiology , Potassium Channels, Inwardly Rectifying , Potassium Channels/metabolism , Action Potentials , Calcium Channel Blockers/pharmacology , Cells, Cultured , Humans , Hypoglycemia/blood , Infant, Newborn , Receptors, Drug , Sulfonylurea Receptors , Verapamil/pharmacology
6.
Diabetologia ; 53(2): 321-30, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19855953

ABSTRACT

AIMS/HYPOTHESIS: Defects in pancreatic beta cell turnover are implicated in the pathogenesis of type 2 diabetes by genetic markers for diabetes. Decreased beta cell neogenesis could contribute to diabetes. The longevity and turnover of human beta cells is unknown; in rodents <1 year old, a half-life of 30 days is estimated. Intracellular lipofuscin body (LB) accumulation is a hallmark of ageing in neurons. To estimate the lifespan of human beta cells, we measured beta cell LB accumulation in individuals aged 1-81 years. METHODS: LB content was determined by electron microscopical morphometry in sections of beta cells from human (non-diabetic, n = 45; type 2 diabetic, n = 10) and non-human primates (n = 10; 5-30 years) and from 15 mice aged 10-99 weeks. Total cellular LB content was estimated by three-dimensional (3D) mathematical modelling. RESULTS: LB area proportion was significantly correlated with age in human and non-human primates. The proportion of human LB-positive beta cells was significantly related to age, with no apparent differences in type 2 diabetes or obesity. LB content was low in human insulinomas (n = 5) and alpha cells and in mouse beta cells (LB content in mouse <10% human). Using 3D electron microscopy and 3D mathematical modelling, the LB-positive human beta cells (representing aged cells) increased from >or=90% (<10 years) to >or=97% (>20 years) and remained constant thereafter. CONCLUSIONS/INTERPRETATION: Human beta cells, unlike those of young rodents, are long-lived. LB proportions in type 2 diabetes and obesity suggest that little adaptive change occurs in the adult human beta cell population, which is largely established by age 20 years.


Subject(s)
Insulin-Secreting Cells/cytology , Lipofuscin/metabolism , Adult , Age Distribution , Aging/physiology , Animals , Biomarkers/metabolism , Cause of Death , Cell Division , Diabetes Mellitus, Type 2/pathology , Humans , Insulin-Secreting Cells/pathology , Insulin-Secreting Cells/physiology , Macaca mulatta , Mice , Mice, Inbred C57BL , Models, Theoretical , Pancreas/cytology , Pancreas/pathology , Tissue Donors
7.
Diabetologia ; 52(8): 1566-78, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19440689

ABSTRACT

AIMS/HYPOTHESIS: The aim of this study was to characterise electrical activity, ion channels, exocytosis and somatostatin release in human delta cells/pancreatic islets. METHODS: Glucose-stimulated somatostatin release was measured from intact human islets. Membrane potential, currents and changes in membrane capacitance (reflecting exocytosis) were recorded from individual human delta cells identified by immunocytochemistry. RESULTS: Somatostatin secretion from human islets was stimulated by glucose and tolbutamide and inhibited by diazoxide. Human delta cells generated bursting or sporadic electrical activity, which was enhanced by tolbutamide but unaffected by glucose. Delta cells contained a tolbutamide-insensitive, Ba(2+)-sensitive inwardly rectifying K(+) current and two types of voltage-gated K(+) currents, sensitive to tetraethylammonium/stromatoxin (delayed rectifying, Kv2.1/2.2) and 4-aminopyridine (A current). Voltage-gated tetrodotoxin (TTX)-sensitive Na(+) currents contributed to the action potential upstroke but TTX had no effect on somatostatin release. Delta cells are equipped with Ca(2+) channels blocked by isradipine (L), omega-agatoxin (P/Q) and NNC 55-0396 (T). Blockade of any of these channels interferes with delta cell electrical activity and abolishes glucose-stimulated somatostatin release. Capacitance measurements revealed a slow component of depolarisation-evoked exocytosis sensitive to omega-agatoxin. CONCLUSIONS/INTERPRETATION: Action potential firing in delta cells is modulated by ATP-sensitive K(+)-channel activity. The membrane potential is stabilised by Ba(2+)-sensitive inwardly rectifying K(+) channels. Voltage-gated L- and T-type Ca(2+) channels are required for electrical activity, whereas Na(+) currents and P/Q-type Ca(2+) channels contribute to (but are not necessary for) the upstroke of the action potential. Action potential repolarisation is mediated by A-type and Kv2.1/2.2 K(+) channels. Exocytosis is tightly linked to Ca(2+)-influx via P/Q-type Ca(2+) channels. Glucose stimulation of somatostatin secretion involves both K(ATP) channel-dependent and -independent processes.


Subject(s)
Exocytosis/physiology , Somatostatin-Secreting Cells/physiology , Somatostatin/metabolism , Diazoxide/pharmacology , Glucose/pharmacology , Humans , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Membrane Potentials/drug effects , Membrane Potentials/physiology , Patch-Clamp Techniques , Pyrimidines/pharmacology , RNA/genetics , Reverse Transcriptase Polymerase Chain Reaction , Somatostatin-Secreting Cells/metabolism , Tolbutamide/pharmacology
8.
Trends Cell Biol ; 7(10): 408-13, 1997 Oct.
Article in English | MEDLINE | ID: mdl-17708991

ABSTRACT

The highly conserved ubiquitin polypeptide functions by covalently modifying other proteins. This modification has a well-established role in facilitating substrate degradation by the proteasome and can regulate some proteins by ways other than targeting them to the proteasome. It has now emerged that proteins bearing only distant similarity to ubiquitin can also be attached to specific proteins. The consequences of most of these modifications are not yet understood. However, two recent papers on one ubiquitin-like protein, SUMO-1, demonstrate a role in targeting a protein crucial for nucleocytoplasmic trafficking to the nuclear pore complex. These and other recent findings suggest a much wider influence of the 'ubiquitin system' on cell biology and raise intriguing regulatory and mechanistic questions.

9.
Science ; 258(5087): 1485-8, 1992 Nov 27.
Article in English | MEDLINE | ID: mdl-1359646

ABSTRACT

An adeno-associated virus vector encoding an antisense RNA was used to transduce stable intracellular resistance to human immunodeficiency virus-1 (HIV-1) in human hemopoietic and non-hemopoietic cell lines. The antisense targets are present in all HIV-1 transcripts and include the TAR sequence, which is critical for transcription and virus replication, and the polyadenylation signal. Cell lines expressing antisense RNA showed up to 95 percent inhibition of gene expression directed by the HIV-1 long terminal repeat and greater than 99 percent reduction in infectious HIV-1 production, with no detectable cellular toxicity. Because of their efficient transcription and inability to recombine with HIV-1, adeno-associated virus vectors represent a promising form of anti-retroviral gene therapy.


Subject(s)
Dependovirus/genetics , Genetic Vectors/genetics , HIV-1/genetics , RNA, Antisense/genetics , Base Sequence , CD4-Positive T-Lymphocytes/microbiology , Cell Line , Chloramphenicol O-Acetyltransferase/genetics , Drug Resistance, Microbial/genetics , Gene Products, tat/genetics , HIV Long Terminal Repeat/genetics , HIV-1/physiology , Humans , Molecular Sequence Data , Neomycin/pharmacology , RNA, Messenger/genetics , RNA, Viral/genetics , Transfection , Virus Replication/genetics , tat Gene Products, Human Immunodeficiency Virus
10.
Science ; 197(4301): 391-3, 1977 Jul 22.
Article in English | MEDLINE | ID: mdl-877563

ABSTRACT

Surgical removal of subcutaneous fat depots in weanling rats leads to a regenerative response. If the rats are fed a diet high in fat, adipose mass and adipocyte number are precisely restored within 7 months of surgery. Thus, under appropriate experimental circumstances, compensatory hyperplasia will occur in adipose tissues of the rat.


Subject(s)
Adipose Tissue/physiology , Regeneration , Adipose Tissue/cytology , Age Factors , Animals , Dietary Fats/metabolism , Inguinal Canal , Obesity/pathology , Rats
11.
Science ; 197(4301): 393-6, 1977 Jul 22.
Article in English | MEDLINE | ID: mdl-877564

ABSTRACT

Lipectomized and sham-operated rats were fed a high-fat diet to induce hyperphagia and rapid fat accumulation. Lipectomized rats with 25% fewer adipocytes were less hyperphagic and accumulated less fat, but their adipocytes remained equal in size to adipocytes of controls. A role for adipocyte size in fat storage regulation and food intake control is postulated.


Subject(s)
Adipose Tissue/physiology , Feeding Behavior/physiology , Obesity/etiology , Adipose Tissue/cytology , Age Factors , Animals , Epididymis , Inguinal Canal , Male , Rats
12.
Science ; 247(4943): 715-8, 1990 Feb 09.
Article in English | MEDLINE | ID: mdl-2137259

ABSTRACT

The role of exocytosis of major histocompatibility complex (MHC) class I molecules in the presentation of antigens to mouse cytotoxic T lymphocytes (CTLs) was examined by use of a recombinant vaccinia virus that expresses the E19 glycoprotein from adenovirus. E19 blocked the presentation of vaccinia and influenza virus proteins to CTLs in a MHC class I allele-specific manner identical to its inhibition of MHC class I transport from the endoplasmic reticulum. This finding indicates that (i) the relevant parameter for antigen presentation is the rate of MHC class I molecule exocytosis, not the level of class I cell surface expression, and (ii) association of class I molecules with antigen is likely to occur within the endoplasmic reticulum.


Subject(s)
Antigen-Presenting Cells/ultrastructure , Antigens/immunology , Endoplasmic Reticulum/immunology , Histocompatibility Antigens Class I/metabolism , T-Lymphocytes, Cytotoxic/immunology , Adenovirus Early Proteins , Animals , Antigen-Presenting Cells/drug effects , Antigen-Presenting Cells/immunology , Antigens, Viral/immunology , Antiviral Agents , Biological Transport , Brefeldin A , Cell Line , Cyclopentanes/pharmacology , Exocytosis , Glycoproteins/analysis , H-2 Antigens/immunology , Histocompatibility Antigens Class I/immunology , Mice , Mice, Inbred A , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred CBA , Oncogene Proteins, Viral/analysis , Orthomyxoviridae Infections/immunology , Recombinant Proteins/immunology , Vaccinia virus/immunology
13.
Article in English | MEDLINE | ID: mdl-34527761

ABSTRACT

This commentary outlines the development and current status of the UK Islet Transplant Programme in the UK. The author makes the case that it is now time for similar fully funded beta-cell programmes to be made available in many other countries as well.

14.
Scott Med J ; 53(3): 8-12, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18780518

ABSTRACT

UNLABELLED: Imatinib is a tyrosine kinase inhibitor, which selectively antagonises the BCR-ABL molecular pathway which causes chronic myeloid leukaemia (CML). Imatinib was first approved by the Scottish Medicines Consortium (SMC) in January 2002 with the recommendation that its use be audited. The cost of the drug has major financial implications for health resources. METHODS: All imatinib usage since its first prescription in Scotland in September 2000 to July 2003 was audited through pharmacy records and through the Scotland Leukaemia Registry (SLR), an existing national registry of patients with CML. RESULTS: One hundred and four patients in Chronic Phase (CP), 36 in Accelerated Phase (AP) and five in Blast Phase (BP) received imatinib. The median duration of therapy was not reached for CFP 17 months for AFP and two months for BP patients. Major (complete) cytogenetic response rates were 74% (63%) and 38% (24%) respectively for CP and APR Overall survival for all CP patients from the start of imatinib therapy was 94% at one year, 91% at two years and 83% at three years. An audit of the effectiveness of the SLR as an auditing agency, showed complete registration in 95% of cases. CONCLUSIONS: We believe such data collection should be an important ongoing resource for assessing outcomes in a rare form of leukaemia but one which already has major implications for health economics and will continue to do so given the future development of dual tyrosine kinase inhibitors for imatinib resistant cases.


Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Benzamides , Dose-Response Relationship, Drug , Female , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Registries , Scotland
15.
J Clin Invest ; 100(7): 1888-93, 1997 Oct 01.
Article in English | MEDLINE | ID: mdl-9312191

ABSTRACT

The neonatal disorder persistent hyperinsulinemic hypoglycemia of infancy (PHHI) arises as the result of mutations in the subunits that form the ATP-sensitive potassium (KATP) channel in pancreatic beta cells, leading to insulin hypersecretion. Diazoxide (a specific KATP channel agonist in normal beta cells) and somatostatin (octreotide) are the mainstay of medical treatment for the condition. To investigate the mechanism of action of these agents in PHHI beta cells that lack KATP currents, we applied patch clamp techniques to insulin-secreting cells isolated from seven patients with PHHI. Five patients showed favorable responses to medical therapy, and two were refractory. Our data reveal, in drug-responsive patients, that a novel ion channel is modulated by diazoxide and somatostatin, leading to termination of the spontaneous electrical events that underlie insulin hypersecretion. The drug-resistant patients, both of whom carried a mutation in one of the genes that encode KATP channel subunits, also lacked this novel K+ channel. There were no effects of diazoxide and somatostatin on beta cell function in vitro. These findings elucidate for the first time the mechanisms of action of diazoxide and somatostatin in infants with PHHI in whom KATP channels are absent, and provide a rationale for development of new therapeutic opportunities by K+ channel manipulation in PHHI treatment.


Subject(s)
Diazoxide/therapeutic use , Hydrochlorothiazide/therapeutic use , Hyperinsulinism/drug therapy , Hypoglycemia/drug therapy , Islets of Langerhans/drug effects , Membrane Proteins , Octreotide/therapeutic use , Potassium Channels, Inwardly Rectifying , Repressor Proteins/genetics , Saccharomyces cerevisiae Proteins , Blood Glucose/analysis , Cell Membrane/drug effects , Disease Management , Electrophysiology , Glycosyltransferases , Humans , Hyperinsulinism/congenital , Hypoglycemia/congenital , Infant, Newborn , Potassium Channels/drug effects , Potassium Channels/genetics , Pyridines/pharmacology , Somatostatin/pharmacology , Thiadiazines/pharmacology
16.
Leukemia ; 20(3): 444-50, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16424877

ABSTRACT

Few large demographic studies of acute myeloid leukemia (AML) are derived from population-based registries. Demographic and karyotypic data were provided for AML cases from two regional leukemia registry databases in Scotland and the Northern Region of England. A population-based dataset was compiled, comprising 1709 patients aged >16 years (1235 North England/474 Scotland patients). The most common cytogenetic abnormalities involved chromosomes 5 and/or 7 (17%). Patients with the following abnormal chromosome 5/7 combinations: -5, del(5q), -5/-7 and del(5q)/-7 represented a significantly older population (P < 0.01, ANOVA). t(8;21) was the only 'favourable' karyotype found in older age. Karyotypic complexity varied within chromosome 5/7 combination groups; those containing -5, -5/-7, -5/del(7q), del(5q)/-7 or del(5q)/del(7q) combinations were significantly more frequently complex than those containing -7 and del(7q) (P < 0.01, chi2 test). Additional recurring cytogenetic abnormalities within complex karyotypes containing chromosome 5/7 combinations included (in order of frequency), abnormalities of chromosomes 17, 12, 3 and 18. Complex karyotypes not involving chromosomes 5 or 7 represented 30% of all complex karyotypes, occurred in younger patients than those involving chromosomes 5 and 7, and frequently included additional trisomy 8 (26%). In conclusion, we describe subgroups within adverse karyotypes, with different demographics, degree of complexity and additional chromosome abnormalities.


Subject(s)
Leukemia, Myeloid/genetics , Population Surveillance , Acute Disease , Adult , Demography , Female , Humans , Male , Registries
17.
Transplant Proc ; 49(10): 2327-2329, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29198671

ABSTRACT

BACKGROUND: Etanercept is widely used as an antiinflammatory drug to improve engraftment after intraportal islet transplantation. In contrast to other immunosuppressive agents, very little is known about detrimental effects of etanercept on islets. The aim of this pilot study was to define the toxic range of etanercept. METHODS: Human islets isolated from 8 donors were cultured for 4-5 days at 37°C in culture medium supplemented with etanercept at concentrations from 2.5 to 40 µg/mL, corresponding to potential in vivo levels within the portal vein. After culture, islet equivalent (IEQ) yield, fragmentation index (islet number/IEQ), purity, viability, and stimulated insulin release (2 vs 20 mmol/L) were assessed and normalized to islets before culture. RESULTS: Yield (73 ± 8%) and viability (91 ± 4%) were highest with 5 µg/mL etanercept. Islet loss was evident when etanercept was ≥10 µg/mL (55 ± 7%; P < .05 vs control). Fragmentation (154 ± 34%; P < .05) was markedly increased and viability (81 ± 4%, P < .05) markedly decreased with etanercept >10 µg/mL. The accumulation of cell debris at concentrations ≥20 µg/mL resulted in a significant reduction of islet purity (84 ± 3%; P < .05). Etanercept did not interfere with stimulated insulin secretion at concentrations ≤10 µg/mL. The maximum stimulation index was noted at 2.5 µg/mL (1.8 ± 0.1). CONCLUSIONS: Etanercept is tolerated by isolated human islets at concentrations <10 µg/mL. Our data suggest that the tight range between benefit and toxicity should be considered for dosage and administration of etanercept.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Etanercept/pharmacology , Islets of Langerhans/drug effects , Maximum Tolerated Dose , Cells, Cultured , Culture Media , Humans , Insulin/metabolism , Insulin Secretion , Islets of Langerhans Transplantation/methods , Pilot Projects
18.
J Vet Intern Med ; 31(6): 1822-1826, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28913839

ABSTRACT

BACKGROUND: Torsemide use for congestive heart failure (CHF) has been reported, but prescription frequency is unknown. Commercially available tablet sizes in North America limit dosing precision, indicating a need to evaluate its strength and stability in suspension. OBJECTIVES: To determine the frequency of torsemide prescriptions and to determine a beyond use date (BUD) of a compounded suspension of torsemide for oral administration stored under 2 temperature conditions for 90 days. ANIMALS: No animals used. METHODS: Pharmacy records were retrospectively reviewed for torsemide and furosemide prescriptions from 2008 to 2015 at 2 veterinary referral centers. After preliminary strength testing, compounded torsemide suspension (5 mg/mL) for oral administration was prepared using torsemide tablets suspended in OraPlus:OraSweet 1:1, buffered to a pH of 8.3 and stored at refrigeration (2-8°C) and room temperature (20-25°C) in 2 oz amber plastic bottles. Samples were analyzed by reverse phase high-performance liquid chromatography (RP-HPLC) on days 0, 14, 30, 60, and 90. RESULTS: Prescriptions for torsemide increased from 2008 to 2015. Analysis of the torsemide 5 mg/mL suspension for oral administration at each time point met United States Pharmacopeia (USP) requirements for torsemide content of 90-110% of label claim. The average strength at 90 days decreased to 92 ± 3% at 2-8°C and 95 ± 2% at 20-25°C. Stability testing did not detect unknown impurities. CONCLUSIONS: Increasing torsemide use warrants availability of a validated and stable compounded formulation. Our results support the assignment of a 90-day BUD for torsemide 5 mg/mL suspension for oral administration compounded in OraPlus:Sweet 1:1 buffered to a pH of 8.3.


Subject(s)
Drug Compounding/veterinary , Pharmaceutical Vehicles/chemistry , Sulfonamides/chemistry , Administration, Oral , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Drug Stability , Drug Storage , Furosemide/administration & dosage , Pharmaceutical Solutions , Refrigeration , Sulfonamides/administration & dosage , Suspensions , Temperature , Torsemide
19.
Transplant Proc ; 49(10): 2330-2332, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29198672

ABSTRACT

BACKGROUND: Mesenchymal stem cells (MSCs) are protective for islets when cotransplanted in a hypoxic environment. However, the risk of neoplasia is increased when MSCs are transplanted into immunosuppressed patients. This initial study aimed to investigate whether the production of protective factors from MSC can be stimulated by different culture conditions to benefit human islets cultured in hypoxia. METHODS: MSC were isolated from human adipose tissue and cultured for 2 days in supplemented Minimum Essential Media α (MEMα) and 21% (21%-MEMα) or 1% oxygen (1%-MEMα). Native MEMα served as control. After MSC harvesting, cell-depleted media were frozen at -20°C until use for human islet culture in 2% oxygen for 72-96 hours before islet characterization. Data were normalized to control islets cultured in native MEMα and 2% oxygen (mean ± SEM). RESULTS: After culture in 21%- or 1%-MEMα, islet recovery increased to 117 ± 12% (NS) and 138 ± 12% (P < .05), respectively. Viability did not change after culture in native MEMα (59 ± 2%), 21%-MEMα (59 ± 3%), or 1%-MEMα (61 ± 3%). Compared with control samples, the glucose stimulation index was increased after culture in 21%-MEMα (P < .05) or 1%-MEMα (P < .05). Overall survival was higher in 1%-MEMα (143 ± 14%) than in 21%-MEMα (119 ± 14%; NS) or native MEMα (P < .05). CONCLUSIONS: This study demonstrates that MSC-preconditioned MEMα increases survival and in vitro function of hypoxic human islets. These findings indicate that hypoxic MSCs seem to produce factors that improve survival of islets suffering from hypoxia.


Subject(s)
Culture Media, Conditioned/pharmacology , Hypoxia , Islets of Langerhans/drug effects , Mesenchymal Stem Cells , Adipose Tissue/cytology , Humans , Male , Mesenchymal Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL